Skip to main content
. Author manuscript; available in PMC: 2022 Jan 1.
Published in final edited form as: Clin Cancer Res. 2021 Feb 10;27(13):3543–3548. doi: 10.1158/1078-0432.CCR-20-4224

Figure 1. Response characteristics in patients with ALK-mutant or amplified neuroblastoma treated with crizotinib at the recommended phase 2 dose.

Figure 1.

This panel shows response onset duration along with exact ALK mutation for patients with neuroblastoma treated with crizotinib. The length of the bar shows the time until the patient had a PR, CR or came off protocol therapy due to disease progression. Therapy duration did not exceed 15 months. PR, partial response; CR, complete response.